| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P50 | author | Giuseppe Patti | Q37370554 |
| Rossella Marcucci | Q42167382 | ||
| Marco Valgimigli | Q44964242 | ||
| George D Dangas | Q63256402 | ||
| P2093 | author name string | Hyo-Soo Kim | |
| Somjot S Brar | |||
| Matthew J Price | |||
| Thomas Cuisset | |||
| Nicoline J Breet | |||
| Jurrien ten Berg | |||
| Germano DiSciascio | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| collaboration | Q1145523 | ||
| data collaboration | Q96060107 | ||
| P304 | page(s) | 1945-1954 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data | |
| P478 | volume | 58 |
| Q35126038 | A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study |
| Q90444708 | A pharmacodynamics comparison of prasugrel and clopidogrel in patients undergoing hemodialysis |
| Q38440842 | ARCTIC: Additional proof against antiplatelet adjusted therapy |
| Q99712325 | Acute thrombosis of everolimus-eluting platinum chromium stent caused by impaired prasugrel metabolism due to cytochrome P450 enzyme 2B6*2 (C64T) polymorphism: a case report |
| Q38037121 | Advances in the monitoring of anti-P2Y12 therapy. |
| Q36087455 | An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel |
| Q89395850 | Anti-platelet Therapy Resistance - Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities |
| Q40386250 | Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation |
| Q28550517 | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database |
| Q37059195 | Antiplatelet agents in clinical practice and their haemorrhagic risk. |
| Q93379484 | Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare |
| Q37708274 | Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers. |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q92051447 | Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation |
| Q50862709 | Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. |
| Q41040676 | CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions |
| Q35210009 | Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial |
| Q38183489 | Cangrelor for treatment of arterial thrombosis |
| Q38413752 | Carotid Endarterectomy on Antiplatelet Agents in the Era of Point-of-Care Testing |
| Q38099541 | Cigarette smoking and clopidogrel interaction |
| Q48183000 | Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response |
| Q89751378 | Clinical Implications of "Tailored" Antiplatelet Therapy in Patients With Chronic Total Occlusion |
| Q38372990 | Clinical efficacy and safety of cilostazol: a critical review of the literature |
| Q38380465 | Clinical evidence for oral antiplatelet therapy in acute coronary syndromes |
| Q52593402 | Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. |
| Q36178772 | Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation |
| Q38283422 | Clopidogrel use in end-stage kidney disease. |
| Q45342015 | Clopidogrel, CYP2C19, and a Black Box. |
| Q61806038 | Comparison of Clopidogrel and Ticlopidine/ in Patients With Clopidogrel Resistance and Carotid Stenting |
| Q90457305 | Comparison of Shear Stress-Induced Thrombotic and Thrombolytic Effects Among 3 Different Antithrombotic Regimens in Patients With Acute Coronary Syndrome |
| Q87488294 | Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction |
| Q57211755 | Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in s |
| Q26829251 | Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding |
| Q38079934 | Controversies in the use & implementation of drug-eluting stent technology. |
| Q34180883 | Coronary intervention. 2012 update |
| Q33760816 | Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome |
| Q50854235 | Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. |
| Q92616771 | Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor |
| Q88195979 | Current Concepts in the Clinical Utility of Platelet Reactivity Testing |
| Q48180649 | Delayed ipsilateral parenchymal hemorrhage following flow diversion for the treatment of anterior circulation aneurysms. |
| Q47834734 | Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays |
| Q64118507 | Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor |
| Q39025194 | Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? |
| Q50980833 | Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. |
| Q64887539 | Early stent thrombosis after superficial femoral artery stenting successfully treated with transcatheter rheolytic thrombectomy in a patient with reduced aspirin responsiveness. |
| Q38023512 | Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis |
| Q38396250 | Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study |
| Q47792745 | Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. |
| Q98243201 | Efficacy and Safety of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study |
| Q41875999 | Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials |
| Q92242416 | Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel |
| Q42245258 | Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity |
| Q37497555 | Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. |
| Q52589473 | Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). |
| Q96025075 | Genome-wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium (ICPC) |
| Q48246774 | Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. |
| Q45823009 | Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness |
| Q58698099 | High On-Treatment Platelet Reactivity in Danish Hyper-Acute Ischaemic Stroke Patients |
| Q38391222 | High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
| Q35033441 | Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects |
| Q50662100 | Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibiti |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q51108799 | Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation. |
| Q93092007 | Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-Deficient Mice |
| Q38071262 | Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease. |
| Q34283808 | Is there attenuation of benefit of invasive therapy in patients with chronic kidney disease? Results from randomized trials and registry data |
| Q38023285 | Late stent thrombosis: the last remaining obstacle in coronary interventional therapy |
| Q48663766 | Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy |
| Q58799733 | Metabolism of ticagrelor in patients with acute coronary syndromes |
| Q46171896 | Monitoring persistent platelet reactivity in patients with unprotected left main stenting |
| Q93379475 | Monitoring platelet function: what have we learned from randomized clinical trials? |
| Q41926971 | Multiple and Contemporary Coronary Thrombosis inspite of Low Platelet Function Response |
| Q38817144 | New directions for pharmacotherapy in the treatment of acute coronary syndrome. |
| Q37703289 | New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study |
| Q58123961 | No Differences in Levels of Circulating Progenitor Endothelial Cells or Circulating Endothelial Cells Among Patients Treated With Ticagrelor Compared With Clopidogrel During Non- ST -Segment-Elevation Myocardial Infarction |
| Q38366950 | Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy. |
| Q38257119 | Novel antiplatelet agents in acute coronary syndrome |
| Q38802950 | Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions |
| Q38542096 | P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use |
| Q50478034 | P2Y12 platelet function assay for assessment of bleeding risk in coronary artery bypass grafting. |
| Q39221284 | P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation |
| Q38156786 | Personalized antiplatelet therapy: state of the art. |
| Q39382840 | Personalizing antiplatelet therapies: What have we learned from recent trials? |
| Q38040698 | Personalizing antiplatelet therapy with clopidogrel. |
| Q62607023 | Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status |
| Q38065738 | Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. |
| Q36216424 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. |
| Q38007894 | Platelet function and inhibition in ischemic heart disease |
| Q38068348 | Platelet function monitoring and clopidogrel |
| Q38094681 | Platelet function testing and tailored antiplatelet therapy |
| Q38842001 | Platelet function testing as a biomarker for efficacy of antiplatelet drugs |
| Q51746988 | Platelet function testing in contemporary clinical and interventional practice. |
| Q38080466 | Platelet function testing in patients with acute coronary syndrome |
| Q38515562 | Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature. |
| Q44621004 | Platelet function: new drugs, new assays : possible impacts on operative medicine? |
| Q94476029 | Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis |
| Q44587286 | Platelet reactivity after coronary stenting |
| Q36244001 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study |
| Q53240082 | Platelet reactivity in patients undergoing transcatheter aortic valve implantation. |
| Q51306353 | Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. |
| Q45912513 | Point of care platelet function testing in routine neurointerventional care is unjustified. |
| Q30877943 | Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting |
| Q39822915 | Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome |
| Q37022618 | Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes |
| Q55072550 | Recent progress and market analysis of anticoagulant drugs. |
| Q88381848 | Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions |
| Q37039218 | Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients |
| Q57764181 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel a |
| Q44264585 | Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report |
| Q37973457 | Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? |
| Q58776094 | Role of platelet α2-adrenoreceptor in biological low response to Clopidogrel for patients with non cardioembolic ischemic stroke or transient ischemic attack |
| Q38393614 | Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. |
| Q39187857 | Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity |
| Q38647047 | Stent Thrombosis after Rescue Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction |
| Q38014979 | Stent thrombosis in patients with chronic kidney disease |
| Q41962888 | Stent thrombosis: incidence, predictors and new technologies |
| Q34282119 | Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin |
| Q43245864 | The CYP2C19(∗)1/(∗)2 Genotype Does Not Adequately Predict Clopidogrel Response in Healthy Malaysian Volunteers |
| Q55431233 | The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". |
| Q38082467 | The future of inpatient anticoagulation management |
| Q34763870 | The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis |
| Q26824694 | The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis |
| Q38069896 | Ticagrelor: the first novel reversible P2Y(12) inhibitor |
| Q36357988 | Translating from the rivers of Babylon to the coronary bloodstream |
| Q38847255 | Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions. |
| Q55547651 | Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. |
Search more.